Friday, July 10, 2026
🇺🇸 FDA

pharma · Advanced Refractory Solid Tumors

CStone Pharmaceuticals

Cstone Pharmaceuticals Ireland Limited

NovaPharmaNews editorial coverage mentioning CStone Pharmaceuticals — regulatory, clinical, and market analysis.

Website Investor relations
Shanghai, CN HQ
2016 Founded
193 Employees
EMA registrant Type
Company details
Status
Public
HQ
Shanghai, CN
Founded
2016
Employees
193
Programs
1
Drugs
1
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning CStone Pharmaceuticals — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning CStone Pharmaceuticals — regulatory, clinical, and market analysis.

All News Analysis

1 articles

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
High impact Analysisnon-small cell lung cancerJun 6, 2026

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.